Scarica l'app Stockscreener
18.41
1.60%
-0.30
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$18.71
Aprire:
$18.75
Volume 24 ore:
88,258
Relative Volume:
0.09
Capitalizzazione di mercato:
$2.32B
Reddito:
$181.74M
Utile/perdita netta:
$-296.81M
Rapporto P/E:
-10.77
EPS:
-1.71
Flusso di cassa netto:
$-402.70M
1 W Prestazione:
-14.01%
1M Prestazione:
-10.15%
6M Prestazione:
-26.42%
1 anno Prestazione:
-35.11%
Intervallo 1D:
$18.21
$18.79
Intervallo di 1 settimana:
$18.03
$21.25
Portata 52W:
$17.05
$39.83
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Nome
Arrowhead Pharmaceuticals Inc
Settore
Industria
Telefono
626-696-4702
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Confronta ARWR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ARWR | 18.45 | 2.32B | 181.74M | -296.81M | -402.70M | -1.71 |
| VRTX | 447.55 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.92 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.88 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.41 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-04 | Iniziato | BofA Securities | Buy |
| 2023-09-19 | Iniziato | Citigroup | Neutral |
| 2023-07-21 | Iniziato | TD Cowen | Outperform |
| 2023-05-12 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-12 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Ripresa | Goldman | Buy |
| 2021-08-06 | Reiterato | Chardan Capital Markets | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-19 | Iniziato | Citigroup | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Iniziato | Goldman | Neutral |
| 2020-01-21 | Iniziato | SVB Leerink | Underperform |
| 2019-12-13 | Iniziato | Oppenheimer | Perform |
| 2019-11-29 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-27 | Reiterato | B. Riley FBR | Buy |
| 2019-11-25 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Reiterato | Chardan Capital Markets | Buy |
| 2019-10-03 | Iniziato | Robert W. Baird | Outperform |
| 2018-09-07 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-08-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Principal Financial Group Inc. Has $5.64 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Familial Chylomicronemia Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Ionis Pharma, Novartis, Akcea Therapeutics, Arrowhead Pharma, Visirna Therapeutics - Barchart
Familial Chylomicronemia Syndrome Market Expected - openPR
Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Tuesday - MarketBeat
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran - BioSpace
Arrowhead seeks FDA nod for rare disease drug - Investing.com
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 6.3%Here's What Happened - MarketBeat
When (ARWR) Moves Investors should Listen - Stock Traders Daily
Privium Fund Management B.V. Has $6.46 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Leerink Partnrs Has Positive Outlook of ARWR FY2024 Earnings - MarketBeat
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results - BioSpace
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences - BioSpace
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - BioSpace
abrdn plc Has $7.77 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Launches FCS Awareness Campaign - Baystreet.ca
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, 'We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - Quantisnow
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaig - GuruFocus.com
In the wake of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest US$108m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St
International Assets Investment Management LLC Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
(ARWR) Long Term Investment Analysis - Stock Traders Daily
Assenagon Asset Management S.A. Has $5.68 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $45.33 - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 6.4%Here's Why - MarketBeat
(ARWR) Trading Signals - Stock Traders Daily
Buffington Mohr McNeal Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com - MarketBeat
State Street Corp's Strategic Acquisition in Arrowhead Pharmaceu - GuruFocus.com
80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - GlobeNewswire
Alpha-1 Antitrypsin Deficiency Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Apic Bio, Dicerna Pharma, Peak Bio, Arrowhead Pharma - The Globe and Mail
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)October 14, 2024 - BioSpace
HC Wainwright Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals (STU:HDP1) EV-to-Revenue : 93.89 (As of Oct. 11, 2024) - GuruFocus.com
Dimensional Fund Advisors LP Boosts Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance
Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highl - GuruFocus.com
Arrowhead Pharmaceuticals Plans $250M Manufacturing Plant in Wisconsin - Pasadena Now
How to Take Advantage of moves in (ARWR) - Stock Traders Daily
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Overweight Rating at Piper Sandler - MarketBeat
Goldman Sachs holds Neutral rating on Arrowhead stock By Investing.com - Investing.com Canada
Arrowhead Pharma maintains Buy rating from TD Cowen after R&D day insights - Investing.com Canada
Arrowhead Pharma retains Overweight rating from Piper Sandler By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year LowShould You Sell? - MarketBeat
ARWR stock touches 52-week low at $18.14 amid market challenges - Investing.com Canada
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Acquired by Millennium Management LLC - MarketBeat
Bank of Montreal Can Buys 30,866 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment? - Simply Wall St
Arrowhead: A First Approval LikelyJury Still Out On Investment Opportunity (ARWR) - Seeking Alpha
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year Low at $18.61 - MarketBeat
Severe Hypertriglyceridemia Market Growth to Accelerate - openPR
Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arrowhead Pharmaceuticals Inc Azioni (ARWR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Vakiener Victoria | Director |
May 02 '24 |
Sale |
23.31 |
1,799 |
41,935 |
30,205 |
| Hamilton James C | Chief Discovery/Trans Medicine |
Apr 01 '24 |
Sale |
28.03 |
6,000 |
168,180 |
204,851 |
| Lu Hongbo | Director |
Mar 19 '24 |
Buy |
28.00 |
1,000 |
28,000 |
32,680 |
| Lu Hongbo | Director |
Mar 20 '24 |
Buy |
27.50 |
1,000 |
27,500 |
33,680 |
| Lu Hongbo | Director |
Mar 18 '24 |
Buy |
27.49 |
1,000 |
27,490 |
31,680 |
| Myszkowski Kenneth Allen | Chief Financial Officer |
Mar 06 '24 |
Sale |
35.19 |
40,000 |
1,407,600 |
400,600 |
| Anzalone Christopher Richard | Chief Executive Officer |
Jan 31 '24 |
Option Exercise |
14.54 |
57,499 |
836,035 |
3,772,547 |
| Anzalone Christopher Richard | Chief Executive Officer |
Jan 31 '24 |
Sale |
32.35 |
57,499 |
1,860,019 |
3,715,048 |
| Hamilton James C | Chief Discovery/Trans Medicine |
Jan 12 '24 |
Sale |
36.89 |
7,940 |
292,904 |
210,851 |
| GIVEN DOUGLAS B | Director |
Jan 11 '24 |
Sale |
38.06 |
2,911 |
110,788 |
129,711 |
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):